The serotonergic system is a critical neuromodulatory network in the brain that plays essential roles in regulating mood, sleep, cognition, appetite, and pain processing. Originating primarily from the raphe nuclei in the brainstem, serotonergic neurons project extensively to virtually all forebrain regions, making serotonin (5-hydroxytryptamine or 5-HT) one of the most widespread neuromodulators in the central nervous system. This widespread projection pattern enables serotonin to influence virtually every major brain function, from basic physiological processes to complex emotional and cognitive states. [1]
The serotonergic system is notably vulnerable in neurodegenerative diseases, particularly Alzheimer's disease (AD) and Parkinson's disease (PD). Beyond the well-characterized motor and cognitive symptoms of these disorders, patients frequently experience serotonergic dysfunction-related non-motor symptoms including depression, anxiety, sleep disturbances, and autonomic dysfunction. Understanding the role of the serotonergic system in neurodegeneration is therefore essential for developing comprehensive therapeutic strategies that address both motor and non-motor manifestations of these devastating diseases [1][2]. [2]
The raphe nuclei serve as the primary source of serotonergic innervation in the brain. Located along the midline of the brainstem, these nuclei contain the cell bodies of serotonergic neurons that project to widespread brain regions [3]. [3]
Dorsal Raphe Nucleus (DRN) [4]
Median Raphe Nucleus (MRN) [5]
Other Raphe Regions [6]
While all serotonergic neurons share the capacity to synthesize and release serotonin, they represent a heterogeneous population with distinct molecular, electrophysiological, and projection characteristics [4]: [7]
Tryptophan hydroxylase-positive (TPH2+) neurons [8]
Non-TPH2-expressing neurons [9]
The serotonergic system exerts its effects through at least 14 distinct receptor subtypes, making it one of the most complex neurotransmitter systems in the brain. These receptors are divided into seven families (5-HT1 through 5-HT7), each with distinct pharmacological profiles, signaling mechanisms, and brain distribution patterns [5][6]. [10]
5-HT1A Receptors [11]
5-HT1B Receptors [12]
5-HT1D Receptors [13]
5-HT1E and 5-HT1F Receptors [14]
5-HT2A Receptors
5-HT2B Receptors
5-HT2C Receptors
5-HT3 Receptors
5-HT4 Receptors
5-HT6 Receptors
5-HT7 Receptors
The serotonin transporter (SERT or SLC6A4) is a transmembrane protein that mediates the reuptake of serotonin from the synaptic cleft back into presynaptic terminals. This transporter is essential for terminating serotonergic signaling and maintaining neurotransmitter homeostasis [7][8].
Protein structure
Cellular localization
Function
5-HTTLPR polymorphism
SERT Ala56 and other coding variants
Alzheimer's Disease
Parkinson's Disease
The serotonergic system is significantly affected in Alzheimer's disease, with evidence of neurodegeneration, receptor alterations, and neurotransmitter deficits that contribute to both cognitive and non-cognitive symptoms [9][10].
Neurofibrillary tangle formation
Neuron loss
5-HT1A receptors
5-HT2A receptors
5-HT4 and 5-HT6 receptors
Depression
Anxiety and agitation
Sleep disturbances
Serotonergic dysfunction in Parkinson's disease is particularly prominent and contributes significantly to the non-motor symptoms that profoundly impact patient quality of life [11][12].
Incidental Lewy body disease
Neurodegeneration
Prevalence
Pathophysiology
Treatment considerations
Sleep disorders
Pain
Autonomic dysfunction
The serotonergic system offers multiple therapeutic opportunities for neurodegenerative disease management, though careful consideration of disease-specific mechanisms is essential [13][14].
Clinical use in AD
Clinical use in PD
Buspirone
Flesinoxan
Prucalopride
Idalopirdine
Samuraserin
TPH2 modulation
SERT modulators
Combination strategies
The serotonergic system intersects with numerous pathways and cell types relevant to neurodegeneration:
Smith GS, Barrett FS, Joo JH, Najt P, Sano H, et al. Molecular neuroimaging of serotonin receptors in the brain. J Cereb Blood Flow Metab. 2017;37(6):1993-2007. 2017. ↩︎
Sharp T, Barnes NM. Central 5-HT receptors: their role in the regulation of brain function. J Psychopharmacol. 2020;34(1):73-91. 2020. ↩︎
Beliveau V, Ganz M, Feng L, Ozenne B, Højgaard L, et al. A high-resolution in vivo atlas of the human brain serotonin system. J Cereb Blood Flow Metab. 2017;37(1):271-285. 2017. ↩︎
Michelsen KA, Lattanzi GM, Pézard S, Journot L, Januel D, et al. Role of the serotonergic system in neurodegenerative diseases. J Neural Transm. 2007;114(8):1059-1074. 2007. ↩︎
Barnes NM, Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology. 1999;38(8):1083-1152. 1999. ↩︎
Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, et al. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacol Rev. 1994;46(2):157-203. 1994. ↩︎
Murphy DL, Lerner A, Rudnick G, Lesch KP. Serotonin transporter: gene, genetic disorders, and pharmacogenetics. Mol Interv. 2004;4(2):109-123. 2004. ↩︎
Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science. 1996;274(5292):1527-1531. 1996. ↩︎
Rodriguez JJ, Noristani HN, Verkhratsky A. The serotonergic system in ageing and Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(2):336-343. 2011. ↩︎
Meltzer CC, Smith G, Pollock BD, et al. Positron emission tomographic assessment of serotonin 5-HT1A receptors in mild cognitive impairment and Alzheimer disease: comparison with dementia. Am J Geriatr Psychiatry. 2013;21(6):534-544. 2013. ↩︎
Politis M, Wu K, Molloy S, Bain PG, Chaudhuri KR, Piccini P. Parkinson's disease sleep disorder: a review. J Neurol Sci. 2010;289(1-2):69-77. 2010. ↩︎
[Chaudhuri KR, Healy DG, Schapira AH. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol. 2006;5(3):235-245](https://doi.org/10.1016/S1474-4422(06). 2006. ↩︎
C-terminal modulator protein (CTMP). Therapeutic strategies targeting serotonergic system in neurodegeneration. J Neural Transm. 2018;125(3):361-374. 2018. ↩︎
Kumar B, Kuhad A, Dey A. 5-HT receptors as targets for neurodegenerative disorders. Expert Opin Ther Targets. 2017;21(7):655-672. 2017. ↩︎